Blueprint Medicines Corp (BPMC)
107.00
+12.14
(+12.80%)
USD |
NASDAQ |
May 02, 16:00
107.02
+0.02
(+0.02%)
After-Hours: 20:00
Blueprint Medicines Gross Profit Margin (Quarterly): 99.64% for Dec. 31, 2023
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 99.64% |
| September 30, 2023 | 95.08% |
| June 30, 2023 | 95.96% |
| March 31, 2023 | 94.98% |
| December 31, 2022 | 87.50% |
| September 30, 2022 | 95.45% |
| June 30, 2022 | 86.63% |
| March 31, 2022 | 91.90% |
| Date | Value |
|---|---|
| December 31, 2021 | 92.95% |
| September 30, 2021 | 84.33% |
| June 30, 2021 | 76.21% |
| March 31, 2021 | 99.53% |
| December 31, 2020 | 99.62% |
| September 30, 2020 | 99.98% |
| June 30, 2020 | 98.48% |
| March 31, 2020 | 99.61% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
76.21%
Minimum
Jun 2021
99.98%
Maximum
Sep 2020
93.62%
Average
95.27%
Median
Gross Profit Margin (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | 80.47% |
| Apellis Pharmaceuticals Inc | 86.40% |
| Ionis Pharmaceuticals Inc | 99.06% |
| Madrigal Pharmaceuticals Inc | -- |
| Sarepta Therapeutics Inc | 87.77% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -161.1% |
| Return on Assets | -43.47% |
| Return on Invested Capital | -102.7% |
| Profit Margin (Quarterly) | -154.1% |
| Operating Margin (Quarterly) | -146.1% |
| Return on Net Operating Assets | -292.2% |